Last updated: 2026-09-16 13:20:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Phathom Pharmaceuticals, Inc. (PHAT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $8.00, with a market capitalisation of $702.22M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.97 to $18.31. This page covers its latest market performance, valuation, price trends and company information.
$702.22M | |
$8.09 | |
$64.54 | |
$2.21 | |
$8.16 | |
44.72K | |
1.31M | |
-- | |
$18.31 | |
$7.97 | |
-- | |
-- |
Phathom Pharmaceuticals, Inc. (PHAT) is trading at $8.00 in pre-market trading as of 2026-09-16 13:18:00, down 2.02% ($0.17) from the previous close of $8.16
Pre-market trading shows how investors are pricing PHAT before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Phathom Pharmaceuticals, Inc. (PHAT) moved from $9.50 to $8.00, representing a decline of 15.84% ($1.51).
The stock traded between $7.97 and $9.65 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.26 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.3%
PHAT is currently trading at $8.00, placing it 0.3% of the way from its 52-week low of $7.97 to its 52-week high of $18.31. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 371 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Phathom Pharmaceuticals, Inc. (PHAT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.